Ph.D. in biochemistry, University of California at San Diego
Master of Science in chemistry, University of Colorado at Boulder
Bachelor of Science in chemistry, University of California at Riverside
Fellowships & Additional Training
Certified Clinical Biochemical Geneticist
Dr. Michael Gibson’s teaching history is founded in biochemistry, genetics and health sciences. He has taught a variety of topics directly related to health sciences throughout his professional career. A selection of his previous courses includes “Human Inborn Errors of Metabolism” and “Biochemical and Molecular Genetics” at Baylor University, and “Molecular Mechanisms of Disease” and the Department of Molecular and Medical Genetics Seminar Series at Oregon Health & Science University. Gibson has given several guest lectures for “Principles of Molecular Medicine” at the University of Pittsburgh’s Graduate School of Public Health, as well as numerous other lectures to audiences of neonatology residents and fellows, medical students, lab medicine faculty, neurology fellows and interns, neuroscience graduate students, and pathology faculty, residents and interns. As Chair of Biological Sciences at Michigan Technological University, Gibson taught biochemistry to undergraduates and graduate students, and a broad course in health to undergraduates.
He has served as mentor or research advisor for Ph.D. candidates at Southern Methodist University, Baylor University, Potchefstroom University (South Africa), and San Diego State University. He has also trained six fellows in biochemical genetics throughout his career.
Gibson is a board-certified clinical biochemical geneticist, and has studied a number of Mendelian disorders of metabolism for the better part of 30 years. His research focus includes understanding the pathophysiology of selected disorders, and developing novel pre-clinical treatment approaches with translational relevance. His laboratory employs pharmacological, cellular and dietary treatment approaches in disorders such as succinic semialdehyde dehydrogenase deficiency, phenylketonuria, maple syrup urine disease, galactosemia and transaldolase deficiency, a defect of the pentose phosphate pathway. His training is in protein chemistry, molecular and neurobiology, neuropharmacology and genetics, and various analytical methodologies. His laboratory is actively interested in hepatic biology and novel approaches to liver regeneration.
Gibson is the chair of the Medical and Scientific Advisory Board of the SSADH Association, which represents children and families affected by Succinic Semialdehyde Dehydrogenase Deficiency (SSADH). Much of his research is focused on this disease.
Gibson joined the Washington State University College of Pharmacy in July 2012. He had been chair of the biological sciences department at Michigan Technology University in Houghton, Mich. Gibson is a past professor at the University of Pittsburgh School of Medicine and the Oregon Health & Science University in Portland.
Positions, Honors & Awards
1984-1986 Postdoctoral Fellow, Dept. Pediatrics, University of California, San Diego, La Jolla, CA
1985-1986 Bank of America-Giannini Foundation Fellow
1986-1988 Assistant Research Biochemist, Dept. Pediatrics, Univ. of California, San Diego, La Jolla, CA
1988-1998 Senior Research Scientist, Institute for Metabolic Disorders, Baylor University Medical Center and Baylor Research Institute, Dallas, Texas
1991-1992 Alexander von Humboldt Foundation Research Fellow, Heidelberg, Germany
1989-1994 Assistant Professor of Biomedical Studies, Baylor University, Waco, Texas
1989-1995 Adjunct Assistant Professor of Biological Sciences, Southern Methodist University, Dallas, TX
1994-1998 Associate Professor of Biomedical Studies, Baylor University, Waco, TX
1995-1998 Adjunct Associate Professor of Biological Sciences, Southern Methodist University, Dallas, TX
1995-1998 Adjunct Associate Professor/Neurology, Univ. Texas Southwestern Medical School, Dallas, TX
1998-2001 Associate Professor, Depts. of Molecular and Medical Genetics and Pediatrics, Oregon Health & Science University, Portland, Oregon
1998-2005 Director, Biochemical Genetics Laboratory, Oregon Health & Science University, Portland, OR
1999-2019 Board Certified Clinical Biochemical Geneticist, American College of Medical Genetics
2001-2005 Professor, Molec. and Medical Genetics, Oregon Health & Science University, Portland, OR
2004– Komrower Memorial Lecturer, Annual Meeting, Society for the Study of Inborn Errors of Metabolism, Amsterdam.
2005-2009 Director, Biochemical Genetics Laboratory, Children’s Hospital of Pittsburgh of UPMC
2005-2009 Professor, Pediatrics, Pathology, Human Genetics, University of Pittsburgh School of Medicine
2009– Pres Professor and Chair, Biological Sciences, Michigan Technological University
2008 NIH Site Visit, PDEGEN (Program in Developmental Endocrinology/Genetics), March 26-28.
Selected Publications and Book Chapters
Malaspina P, Roullet J-B, Pearl PL, Ainslie GR, Vogel KR, Gibson KM (2016) Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism. Neurochem. International [available electronically, June 14, 2016]
Schreiber JM, Pearl PL, Dustin I, Wiggs E, Barrios E, Wassermann EM, Gibson KM, Theodore WH. Biomarkers in a taurine trial for succinic semialdehyde dehydrogenase deficiency. JIMD Rep., in press.
Koenig MK, Bonnen P, Hodgeman R, Riviello J, Chung WK, Bain J, Chiriboga CA, Gibson KM, Pearl PL/ GABA-Transaminase Deficiency, a Severe Early Onset Epileptic Encephalopathy and Movement Disorder. Neurology, submitted.
Wernli C, Finochiaro S, Volken C, Andresen-Streichert H, Buettler A, Gygax D, Salomons GS, Jansen EE, Ainslie GR, Vogel KR, and Gibson KM. Targeted Screening of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD) Employing a Spectrophotometric Assay for g-Hydroxybutyric Acid (GHB) in Biofluids. JIMD Reports, submitted.
Rodan LH, Gibson KM, Pearl PL (2015) Clinical use of CSF neurotransmitters. Pediatr. Neurol. 53(4): 277-286.
Bi W, Bi Y, Gao X, Yan X, Zhang Y, Xue P, Bammert CE, Legalley TD, Michael Gibson K, Bi L, Wang JX. Anti-inflammatory, analgesic and antioxidant activities of novel kyotorphin-nitroxide hybrid molecules. Bioorg Med Chem Lett. 2016 Mar 3 [Epub ahead of print]
Vogel KR, Ainslie GR, Gibson KM. mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. J. Inherited Metab. Dis., in press.
Vogel KR, Ainslie GR, Schmidt MA, WisorJP, Gibson KM. γ−vinyl-GABA (vigabatrin) ocular pathophysiology correlates to transcriptional variations in GABA and glutamate receptors and mTOR pathway function. Molecular Vision, in press.
Attri SV, Singhi P, Wiwattanadittakul N, Goswami JN, Sankhyan N, Salomons SG, Roullet J-B, Parviz M, Gibson KM, Pearl PL. Concordance of Indian twins and worldwide distribution of succinic semialdehyde dehydrogenase (SSADH) deficiency. JIMD Reports, in press.
Bi W, Yue B, Gao X, Yan, Zhang Y, Xue P, Harris J, Legalley TD, Gibson KM, Jia-Xiang W, Bi L (2016) Preservation of mitochondrial function using curcumin-PAK peptide conjugates mitigates acute limb ischemia/reperfusion injury. J. Med. Chem., in press.
Ainslie GR, Vogel KR, Gibson KM. A preliminary pharmacokinetic evaluation and metabolite identification of the GHB receptor antagonist NCS-382 in mouse informs novel therapeutic strategies to treat GHB intoxication. Br. J. Pharmacol., in press.
Vogel KR, Ainslie GR, Jansen EEW, Salomons GS, Gibson KM. mTOR inhibitors correct transcriptional biosignatures of mTOR and oxidant stress in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism. Submitted for publication.
Gibson KM, Jakobs C, Pearl PL. Succinic semialdehyde dehydrogenase deficiency. In: A Clinical Guide to Inherited Metabolic Diseases in Adults, Lachmann R, Hollak C, Sedel F, eds., in press.
Gibson KM, Pastores GM, Pearl PL. Inborn Errors of Metabolism and the Nervous System. In: Bradley’s Neurology in Clinical Practice (NICP), 7th Edition, Pomeroy, SL, editor, Chapter 91, in progress.
Pearl PL, Wiwattanadittakul N, Roullet J-B, Gibson KM. Succinic semialdehyde dehydrogenase deficiency. In: Greenamyre JT, editor-in-chief. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Last updated: [February 18, 2016-most recent update].
Ainslie GR, Gibson KM, Vogel KR (2016) mTOR, autophagy, aminoacidopathies, and human genetic disorders. In: Molecules to Medicine with mTOR, II. mTOR in Genetic Disorders and Neurodegenerative Disease. Maiese, K, ed., chap. 9, pp. 143-166.
Lapalme-Remis S, Lewis E, De Meulemeetser C, Chakraborty P, Gibson KM, Torres CH, Guberman A, Salomons GS, Jakobs C, Ali-Ridha A, Parviz M, Pearl P (2015) Natural History of Succinic Semialdehyde Dehydrdogenase Deficiency through Adulthood. Neurology, in press.
Vogel KR, Ainslie GR, Jansen EEW, Salomons GS, Gibson KM (2015) Torin 1 partially corrects vigabatrin-induced mitochondrial increase in mouse. Ann. Clin. Trans. Neurol. 2(6): 699-706.
Vogel KR, Ainslie GR, Phillips B, Arning E, Bottiglieri T, Shen DD, Gibson KM (2015) Physiological competition of brain phenylalanine accretion: intial pharmacokinetic analyses of aminoisobutyric and methylaminoisobutyric acids in Pahenu2-/- mice. Mol. Genet. Metab., in press.
Yapici NB, Mandalapu S, Gibson KM, Bi L (2015) Targeted fluorescent probes for detection of oxidative stress in the mitochondria. Bioorg Med Chem Lett. 2015 Jul 9. pii: S0960-894X(15)00715-5. doi: 10.1016/j.bmcl.2015.07.011. [Epub ahead of print]
Yapici NB, Bi Y, Li P, Chen X, Yan X, Mandalapu SR, Faucett M, Jockusch S, Ju J, Gibson KM, Pavan WJ, Bi L (2015) Highly stable and sensitive fluorescent probes (LysoProbes) for lysosomal labeling and tracking. Scientific Reports 5: 8576; doi: 10.1038/srep08576
Vogel KR, Ainslie GR, Phillips B, Arning E, Bottiglieri T, Shen DD, Gibson KM (2015) Physiological competition of brain phenylalanine accretion: initial pharmacokinetic analyses of aminoisobutyric and methylaminoisobutyric acids in Pahenu2-/- mice. Molec. Genet. Metab. Rep. 3: 80-87.
Rodan LH, Gibson KM, Pearl PL (2015) Clinical use of CSF neurotransmitters. Pediatr. Neurol. Jun 11. pii: S0887-8994(15)00279-9. doi: 10.1016/j.pediatrneurol.2015.04.016. [Epub ahead of print] Review.
Pearl PL, Gibson KM. (2014) Gamma-Amino Butyric Acid Pathway Disorders. Chap. 10, pp. 133-147. In: Hoffmann GF, Blau N (eds.) Congenital Neurotransmitter Disorders: A Clinical Approach. Nova Science Publishers.
Boston Children’s Hospital and the Department of Neurology, Harvard Medical, Epilepsy Research Seminar, Division of Epilepsy and Clinical Neurophysiology, April 16, 2015, “The GABA-mTOR-mitophagy Triad: Therapeutic Insights for Disordered GABA Metabolism and Vigabatrin-Induced Toxicity”, Host: Dr. Phillip Pearl.
Department of Integrated Physiology and Neuroscience, Washington State University, Pullman, WA. “Man, Mice and Drugs: A Genetic Odyssey in a Heritable Disorder of GABA Metabolism”. Host: Dr. Steven Simasko, Nov. 13, 2015.
SSADH Symposium: A Focus on a Rare Neurotransmitter Disease, March 31-April 1, 2016. Sponsored by Boston Children’s Hospital, Dept. of Neurology. “Historical Timeline of SSADH Deficiency”.